Open-label treatment with citalopram in patients with irritable bowel syndrome: A pilot study

Prakash S. Masand, Sanjay Gupta, Thomas L. Schwartz, Subhdeep Virk, Ahmad Hameed, David S. Kaplan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity. Method: Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001. Results: Twelve (80%) of the 15 subjects reported a ≥ 50% decrease in the presence of abdominal pain, 10 (67%) reported a ≥ 50% reduction in the severity of the symptom, and 12 (80%) reported a ≥ 50% reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (≥ 70% improvement) of abdominal pain. Conclusion: Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS.

Original languageEnglish (US)
Pages (from-to)162-166
Number of pages5
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume7
Issue number4
StatePublished - Dec 20 2005

Fingerprint

Citalopram
Irritable Bowel Syndrome
Abdominal Pain
Gastrointestinal Diseases
Serotonin Uptake Inhibitors
Psychiatry
Comorbidity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Masand, Prakash S. ; Gupta, Sanjay ; Schwartz, Thomas L. ; Virk, Subhdeep ; Hameed, Ahmad ; Kaplan, David S. / Open-label treatment with citalopram in patients with irritable bowel syndrome : A pilot study. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2005 ; Vol. 7, No. 4. pp. 162-166.
@article{e15c6d670c1e49698310d7d52a433b37,
title = "Open-label treatment with citalopram in patients with irritable bowel syndrome: A pilot study",
abstract = "Background: This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity. Method: Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001. Results: Twelve (80{\%}) of the 15 subjects reported a ≥ 50{\%} decrease in the presence of abdominal pain, 10 (67{\%}) reported a ≥ 50{\%} reduction in the severity of the symptom, and 12 (80{\%}) reported a ≥ 50{\%} reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (≥ 70{\%} improvement) of abdominal pain. Conclusion: Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS.",
author = "Masand, {Prakash S.} and Sanjay Gupta and Schwartz, {Thomas L.} and Subhdeep Virk and Ahmad Hameed and Kaplan, {David S.}",
year = "2005",
month = "12",
day = "20",
language = "English (US)",
volume = "7",
pages = "162--166",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

Open-label treatment with citalopram in patients with irritable bowel syndrome : A pilot study. / Masand, Prakash S.; Gupta, Sanjay; Schwartz, Thomas L.; Virk, Subhdeep; Hameed, Ahmad; Kaplan, David S.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 7, No. 4, 20.12.2005, p. 162-166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Open-label treatment with citalopram in patients with irritable bowel syndrome

T2 - A pilot study

AU - Masand, Prakash S.

AU - Gupta, Sanjay

AU - Schwartz, Thomas L.

AU - Virk, Subhdeep

AU - Hameed, Ahmad

AU - Kaplan, David S.

PY - 2005/12/20

Y1 - 2005/12/20

N2 - Background: This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity. Method: Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001. Results: Twelve (80%) of the 15 subjects reported a ≥ 50% decrease in the presence of abdominal pain, 10 (67%) reported a ≥ 50% reduction in the severity of the symptom, and 12 (80%) reported a ≥ 50% reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (≥ 70% improvement) of abdominal pain. Conclusion: Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS.

AB - Background: This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity. Method: Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001. Results: Twelve (80%) of the 15 subjects reported a ≥ 50% decrease in the presence of abdominal pain, 10 (67%) reported a ≥ 50% reduction in the severity of the symptom, and 12 (80%) reported a ≥ 50% reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (≥ 70% improvement) of abdominal pain. Conclusion: Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS.

UR - http://www.scopus.com/inward/record.url?scp=28944450410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944450410&partnerID=8YFLogxK

M3 - Article

C2 - 16163399

AN - SCOPUS:28944450410

VL - 7

SP - 162

EP - 166

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 4

ER -